 Thar’s platform technology creates new patentable versions of small molecule drugs that can solve certain clinical limitations related to bioavailability, safety, efficacy or stability. Our technology is analogous to prodrug technology as we create a new molecule by hydrogen-bonding the parent drug (i.e. on-the market active drug) to a second pharmaceutically-acceptable, non-active molecule in a stoichiometric-based reaction. The result is a molecular change to the parent API that can be protected by a composition-of-matter patent.
This combination changes the physicochemical (solubility, permeability, melting point, etc.) and pharmacokinetic (PK) (bioavailability, onset, and absorption) properties of the parent drug, thus creating potentially enhanced clinical performance. We most often use as the second non-active molecule generally-recognized-as-safe (GRAS) molecules, which is a category of molecules that the FDA has generally identified as safe and non-toxic. Although we change the PK of the drug, we do not change the pharmacology or the pharmacodynamics of the drug. Our new molecules are cleaved in the human gut so that the parent drug is unchanged in the bloodstream. We do not change the basic drug-protein target interaction. From the absorption-distribution-metabolism- excretion (ADME) prospective, we change absorption, but we do not change distribution, metabolism, or excretion of the drug.
| Thar’s technology platform can solve clinical limitations by: |
| |
|
|
Changing the route of delivery: |
| |
 |
IV to oral, Infusion to IV or IM to bolus |
| |
|
Eliminates cost of administration and increases patient convenience |
|
|
Reducing IV, IM or SC suspension and reconstitution problems |
|
|
Increasing speed of onset of action: |
| |
|
Expands patient population by repositioning chronic drugs for acute uses |
|
|
Reducing PK variability |
|
|
Improving safety, reduced side effects and toxicity |
|
|
Reducing polymorphic proliferation, improving stability |
|
|
Managing product lifecycle: |
| |
|
New composition-of-matter IP |
| |
|
Cost-effective and time-efficient regulatory approach with 505(b)(2) filings |
|
| |
| |
|
